HRP20160299T1 - Cjepivo protiv rotavirusa - Google Patents
Cjepivo protiv rotavirusa Download PDFInfo
- Publication number
- HRP20160299T1 HRP20160299T1 HRP20160299TT HRP20160299T HRP20160299T1 HR P20160299 T1 HRP20160299 T1 HR P20160299T1 HR P20160299T T HRP20160299T T HR P20160299TT HR P20160299 T HRP20160299 T HR P20160299T HR P20160299 T1 HRP20160299 T1 HR P20160299T1
- Authority
- HR
- Croatia
- Prior art keywords
- rotavirus
- serotypes
- use according
- infection
- preparation
- Prior art date
Links
- 229940124859 Rotavirus vaccine Drugs 0.000 title 1
- 241000702670 Rotavirus Species 0.000 claims 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 8
- 208000005577 Gastroenteritis Diseases 0.000 claims 6
- 206010067470 Rotavirus infection Diseases 0.000 claims 5
- 229930024421 Adenine Natural products 0.000 claims 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 4
- 108091081024 Start codon Proteins 0.000 claims 4
- 229960000643 adenine Drugs 0.000 claims 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 229940113082 thymine Drugs 0.000 claims 4
- 230000002238 attenuated effect Effects 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 241000617996 Human rotavirus Species 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 1
- 229940069428 antacid Drugs 0.000 claims 1
- 239000003159 antacid agent Substances 0.000 claims 1
- 230000001458 anti-acid effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Claims (13)
1. Upotreba oslabljenog soja ljudskog rotavirusa iz serotipa G1 u pripravi pripravka za induciranje imunosnog odgovora protiv infekcije rotavirusom iz serotipa G1 i najmanje dva ne-G1 serotipa rotavirusa koje se bira iz skupine koju čine: serotipovi G2, G3, G4 i G9, naznačena time što je oslabljeni soj rotavirusa jedna varijanta rotavirusa, ili uglavnom jedna varijanta rotavirusa, koja ima gen VP4 koji u svom nukleotidnom slijedu sadrži najmanje jedno od sljedećeg: adenin (A) na položajima 788 i 802 i timin (T) na položaju 501 od početnog kodona; i/ili koja ima gen VP7 koji u svom nukleotidnom slijedu sadrži najmanje jedno od sljedećeg: timin (T) na položaju 605, adenin (A) na položaju 897, te gvanin (G) na položaju 897 od početnog kodona.
2. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što pripravak može inducirati imunosni odgovor protiv infekcije rotavirusom iz serotipa G1 i najmanje tri ne-G1 serotipa rotavirusa koje se bira iz skupine koju čine: serotipovi G2, G3, G4 i G9.
3. Upotreba u skladu s patentnim zahtjevom 1 ili 2, naznačena time što pripravak može inducirati imunosni odgovor protiv infekcije rotavirusom iz serotipa G1 i iz serotipova G2, G3, G4 i G9.
4. Upotreba u skladu s patentnim zahtjevima 1 do 3, naznačena time što gen VP4 sadrži nukleotidni slijed koji sadrži adeninsku bazu (A) na položajima 788 i 802 i timinsku bazu (T) na položaju 501 od početnog kodona.
5. Upotreba u skladu s patentnim zahtjevima 1 do 4, naznačena time što gen VP7 sadrži nukleotidni slijed koji sadrži timin (T) na položaju 605 i adenin (A) ili gvanin (G) na položaju 897 od početnog kodona.
6. Upotreba u skladu s patentnim zahtjevima 1 do 5, naznačena time što pripravak štiti najmanje 50% u populaciji osoba cijepljenih protiv proljeva i/ili gastroenteritisa i/ili teškog gastroenteritisa uzrokovanih infekcijom rotavirusom iz najmanje dva ne-G1 serotipa.
7. Upotreba u skladu s patentnim zahtjevima 1 do 5, naznačena time što pripravak štiti do 60% u populaciji osoba cijepljenih protiv proljeva uzrokovanog infekcijom rotavirusa iz najmanje dva ne-G1 serotipa.
8. Upotreba u skladu s patentnim zahtjevima 1 do 5, naznačena time što pripravak štiti do 81% protiv gastroenteritisa uzrokovanog infekcijom rotavirusom iz najmanje dva ne-G1 serotipa.
9. Upotreba u skladu s patentnim zahtjevima 1 do 5, naznačena time što pripravak štiti do 83% u populaciji osoba cijepljenih protiv teškog gastroenteritisa uzrokovanog infekcijom rotavirusima iz najmanje dva ne-G1 serotipa, koje se bira iz skupine koju čine G2, G3, G4 i G9.
10. Upotreba u skladu s patentnim zahtjevom 6, 8 i 9, naznačena time što je gastroenteritis uzrokovan infekcijom rotavirusom iz najmanje tri ne-G1 serotipa, koje se bira iz skupine koju čine G2, G3, G4 i G9.
11. Upotreba u skladu s patentnim zahtjevom 10, naznačena time što je gastroenteritis uzrokovan infekcijom serotipovima G2, G3, G4 i G9.
12. Upotreba u skladu s patentnim zahtjevima 1 do 11, naznačena time što je pripravak namijenjen primjeni u dvodoznom režimu.
13. Upotreba u skladu s patentnim zahtjevima 1 do 12, naznačena time što oslabljeni soj ljudskog rotavirusa se formulira s pogodnim farmaceutskim nosačem ili s antacidnim puferom ili s oboje.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49943003P | 2003-09-02 | 2003-09-02 | |
| GBGB0414787.2A GB0414787D0 (en) | 2004-07-01 | 2004-07-01 | Method |
| EP10176849.7A EP2272532B1 (en) | 2003-09-02 | 2004-08-31 | Rotavirus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160299T1 true HRP20160299T1 (hr) | 2016-04-22 |
Family
ID=34276843
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130407TT HRP20130407T1 (en) | 2003-09-02 | 2013-05-08 | Rotavirus vaccine |
| HRP20160299TT HRP20160299T1 (hr) | 2003-09-02 | 2016-03-23 | Cjepivo protiv rotavirusa |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130407TT HRP20130407T1 (en) | 2003-09-02 | 2013-05-08 | Rotavirus vaccine |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP2272532B1 (hr) |
| JP (1) | JP5588586B2 (hr) |
| KR (1) | KR20060126917A (hr) |
| AU (1) | AU2004268375B2 (hr) |
| BR (1) | BRPI0414073A (hr) |
| CA (1) | CA2536734C (hr) |
| HR (2) | HRP20130407T1 (hr) |
| IL (1) | IL173921A0 (hr) |
| IS (1) | IS2922B (hr) |
| MA (1) | MA28035A1 (hr) |
| MX (1) | MXPA06002459A (hr) |
| NO (1) | NO342397B1 (hr) |
| NZ (1) | NZ545639A (hr) |
| PL (2) | PL1660123T3 (hr) |
| RU (1) | RU2368392C2 (hr) |
| SG (1) | SG147465A1 (hr) |
| WO (1) | WO2005021033A2 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090028828A1 (en) * | 2005-08-17 | 2009-01-29 | Glaxosmithkline Biologicals Sa | Rotavirus Vaccine Inducing Heterotypic Cross Protection |
| WO2007081447A2 (en) | 2005-11-22 | 2007-07-19 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
| WO2011138229A1 (en) * | 2010-05-03 | 2011-11-10 | Glaxosmithkline Biologicals S.A. | Novel method |
| SG190419A1 (en) | 2010-12-02 | 2013-06-28 | Oncolytics Biotech Inc | Lyophilized viral formulations |
| AU2011336413B2 (en) | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Liquid viral formulations |
| US10548970B2 (en) | 2015-10-05 | 2020-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human rotavirus G9P[6] strain and use as a vaccine |
| US10550405B2 (en) | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
| EP3596203A4 (en) * | 2018-05-07 | 2021-12-01 | The University Of North Carolina At Chapel Hill | RATIONAL POLYPLOID ADENO-ASSOCIATED VIRUS VECTORS AND METHOD FOR MANUFACTURING AND USING THEREOF |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| JP2849632B2 (ja) | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | ワクチン製剤 |
| ATE170081T1 (de) | 1990-11-16 | 1998-09-15 | Childrens Hosp Medical Center | Humane rotativen, impfstoffe und methoden |
| IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
| HU219808B (hu) | 1992-06-25 | 2001-08-28 | Smithkline Beecham Biologicals S.A. | Adjuvánst tartalmazó vakcinakompozíció és eljárás annak előállítására |
| US6019982A (en) | 1994-08-26 | 2000-02-01 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
| WO1998056415A1 (en) | 1997-06-11 | 1998-12-17 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
| DZ3219A1 (fr) * | 1999-08-17 | 2001-02-22 | Smithkline Beecham Biolog | Vaccin |
-
2004
- 2004-08-31 JP JP2006525097A patent/JP5588586B2/ja active Active
- 2004-08-31 NZ NZ545639A patent/NZ545639A/en unknown
- 2004-08-31 SG SG200807883-4A patent/SG147465A1/en unknown
- 2004-08-31 PL PL04764688T patent/PL1660123T3/pl unknown
- 2004-08-31 KR KR1020067004369A patent/KR20060126917A/ko not_active Application Discontinuation
- 2004-08-31 EP EP10176849.7A patent/EP2272532B1/en active Active
- 2004-08-31 CA CA2536734A patent/CA2536734C/en active Active
- 2004-08-31 RU RU2006106427/13A patent/RU2368392C2/ru not_active IP Right Cessation
- 2004-08-31 PL PL10176849T patent/PL2272532T3/pl unknown
- 2004-08-31 EP EP04764688A patent/EP1660123B1/en active Active
- 2004-08-31 AU AU2004268375A patent/AU2004268375B2/en not_active Ceased
- 2004-08-31 MX MXPA06002459A patent/MXPA06002459A/es active IP Right Grant
- 2004-08-31 BR BRPI0414073-7A patent/BRPI0414073A/pt not_active Application Discontinuation
- 2004-08-31 WO PCT/EP2004/009725 patent/WO2005021033A2/en active Application Filing
-
2006
- 2006-02-23 IS IS8325A patent/IS2922B/is unknown
- 2006-02-23 IL IL173921A patent/IL173921A0/en unknown
- 2006-02-28 NO NO20060976A patent/NO342397B1/no unknown
- 2006-03-10 MA MA28868A patent/MA28035A1/fr unknown
-
2013
- 2013-05-08 HR HRP20130407TT patent/HRP20130407T1/hr unknown
-
2016
- 2016-03-23 HR HRP20160299TT patent/HRP20160299T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG147465A1 (en) | 2008-11-28 |
| EP2272532A3 (en) | 2012-08-01 |
| NZ545639A (en) | 2009-04-30 |
| CA2536734A1 (en) | 2005-03-10 |
| KR20060126917A (ko) | 2006-12-11 |
| EP1660123B1 (en) | 2013-03-13 |
| CA2536734C (en) | 2014-07-08 |
| NO20060976L (no) | 2006-03-31 |
| MXPA06002459A (es) | 2006-06-20 |
| EP2272532A2 (en) | 2011-01-12 |
| AU2004268375B2 (en) | 2010-01-28 |
| RU2006106427A (ru) | 2007-10-10 |
| PL2272532T3 (pl) | 2016-07-29 |
| JP5588586B2 (ja) | 2014-09-10 |
| WO2005021033A3 (en) | 2005-05-06 |
| EP2272532B1 (en) | 2016-02-10 |
| RU2368392C2 (ru) | 2009-09-27 |
| IL173921A0 (en) | 2006-07-05 |
| HRP20130407T1 (en) | 2013-06-30 |
| EP1660123A2 (en) | 2006-05-31 |
| NO342397B1 (no) | 2018-05-14 |
| BRPI0414073A (pt) | 2006-10-24 |
| JP2007516215A (ja) | 2007-06-21 |
| AU2004268375A1 (en) | 2005-03-10 |
| PL1660123T3 (pl) | 2013-08-30 |
| WO2005021033A2 (en) | 2005-03-10 |
| IS2922B (is) | 2015-04-15 |
| IS8325A (is) | 2006-02-23 |
| MA28035A1 (fr) | 2006-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160299T1 (hr) | Cjepivo protiv rotavirusa | |
| HRP20150310T1 (hr) | Cjepivo protiv rotavirusa koje inducira heterotipnu ukriženu zaštitu | |
| Jiang et al. | The role of serum antibodies in the protection against rotavirus disease: an overview | |
| Matsuno et al. | A candidate for a new serotype of human rotavirus | |
| Gouvea et al. | Is rotavirus a population of reassortants? | |
| Choi et al. | Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses | |
| DeMaula et al. | Changes in the outer capsid proteins of bluetongue virus serotype ten that abrogate neutralization by monoclonal antibodies | |
| Greenberg et al. | Rescue and serotypic characterization of noncultivable human rotavirus by gene reassortment | |
| Nagai et al. | Nucleotide sequence homology to bovine viral diarrhea virus 2 (BVDV 2) in the 5′ untranslated region of BVDVs from cattle with mucosal disease or persistent infection in Japan | |
| RU2007101531A (ru) | Субъединичная вакцина против prrsv | |
| Matsuda et al. | Presence of three P types (VP4 serotypes) and two G types (VP7 serotypes) among bovine rotavirus strains | |
| Hasegawa et al. | Isolation of human rotaviruses with a distinct RNA electrophoretic pattern from Indonesia | |
| Lai et al. | Evaluation of molecular strategies to develop a live dengue vaccine | |
| Nishikawa et al. | Comparative analysis of the VP3 gene of divergent strains of the rotaviruses simian SA11 and bovine Nebraska calf diarrhea virus | |
| Nakagomi et al. | Molecular evidence for naturally occurring single VP7 gene substitution reassortant between human rotaviruses belonging to two different genogroups | |
| JP2007516215A5 (hr) | ||
| Hoshino et al. | Analysis by plaque reduction neutralization assay of intertypic rotaviruses suggests that gene reassortment occurs in vivo | |
| Liang et al. | Priming with DNA encoding E2 and boosting with E2 protein formulated with CpG oligodeoxynucleotides induces strong immune responses and protection from Bovine viral diarrhea virus in cattle | |
| MacLachlan et al. | Experiences with new generation vaccines against equine viral arteritis, West Nile disease and African horse sickness | |
| DuPont | Rotaviral Gastroenteritis: Some Recent Developments | |
| ES2273669T5 (es) | Pestivirus que no se propagan. | |
| Domínguez-Gil et al. | Virología: diagnóstico sindrómico de meningitis y encefalitis | |
| Wolfinger et al. | Functional RNA Structures in the 3′ UTR of Mosquito-Borne Flaviviruses | |
| Davis | Measles in the tropics and public health practice | |
| JP2005509591A5 (hr) |